FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / Articles / Read Article

Print

Trinity Capital Provides $25MM in Growth Capital to Neuros Medical

Date: Nov 01, 2023 @ 07:55 AM
Filed Under: Biotechnology

Trinity Capital announced the commitment of $25 million in growth capital to Neuros Medical, Inc., a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life. The growth capital will enable Neuros Medical to augment the recent equity raised and further scale operations to assist with their commercial launch.

Neuros Medical's Altius System incorporates the company's patented platform technology, On-Demand Bioelectric Nerve Block, which patients initiate as needed for targeted pain relief. The technology blocks sensory nerves and has the potential to alleviate pain in nearly one million Americans with phantom limb and residual limb pain, fulfilling a significant need for patients. This system also has the potential to reduce drug dependency as existing treatment options are primarily limited to opioids and gabapentinoids.

Rob Lake, Senior Managing Director, Life Sciences at Trinity, said, "We are proud to partner with Neuros Medical on their journey to improve the lives of those suffering from chronic post-amputation pain, and we look forward to working with their team to support their continued growth."

David Veino, President and Chief Executive Officer of Neuros Medical said, "We appreciate the conviction Trinity has in the Neuros mission and our ability to scale commercialization, delivering this life-changing therapy to a large, underserved amputee population in desperate need of pain relief."

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.